RESEARCH TRIANGLE PARK – GlaxoSmithKline CEO Emma Walmsley sees 2022 as a “landmark year” after the drug giant rejected a bid from Unilever for its consumer health business and plans to move ahead with a spinoff.
“We have ended the year strongly, with another quarter of excellent performance driven by first-class commercial execution, and we enter 2022 with good momentum,” Walmsley said early Wednesday as GSK (NYSE: GSK) delivered financials that beat expectations.
“This is going to be a landmark year for GSK, with a step-change in growth expected and multiple R&D catalysts, including milestones on up to 7 key late-stage pipeline assets,” she explained in a statement.
“2022 is also the year when we demerge our world-leading Consumer Healthcare business. At our capital markets event later this month, we will set out the future growth ambitions and highly attractive financial profile of this business, and the outstanding opportunity it provides for shareholders.”
More coverage:
- Reuters takes an in-depth look at GSK’s financials and future prospects.
- GSK’s earnings report details
GSK maintains an R&D operation in RTP, a significant presence with ViiV Healthcare which GSK owns, and a manufacturing plant in Wendell.
More GSK headlines
GSK’s twin victories: Patent settlement nets $1.2B; FDA OKs longer term of use for AIDS drug
Drug conceived in RTP prevents new HIV infections better than daily pill, offers option for women
COVID-19 vaccine with links to RTP, GSK shows promise in clinical trials
